These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 19112913)
1. [Allogeneic hematopoietic stem cell transplantation following reduced intensity conditioning regimen for treatment of refractory leukemia]. Jiang JL; Yan SK; Yang J; Cai Y; Wan LP; Qin YW; Wang C Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):517-21. PubMed ID: 19112913 [TBL] [Abstract][Full Text] [Related]
2. [Clinical study of allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute lymphocytic leukemia]. Ma X; Wu DP; Sun AN; Fu ZZ; Tang XW; Wu XJ; Liu YJ; Qiu HY; Miao M; Han Y; Jin ZM; Zhao Y; Xue SL; Wang Y; Chen SN; He GS; Zhou HX; Chang HR Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):73-6. PubMed ID: 19563014 [TBL] [Abstract][Full Text] [Related]
3. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296 [TBL] [Abstract][Full Text] [Related]
4. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465 [TBL] [Abstract][Full Text] [Related]
5. [A comparison of clinical outcomes between unrelated donor and HLA-haploidentical donor hematopoietic stem cell transplantation]. Chen F; Wu DP; Sun AN; Ma X; Tang XW; Qiu HY; Miao M; Fu ZZ; Jin ZM; Wang Y; Wu XJ; Chen SN; He GS; Wang XL; Xue SL; Zhao Y; Chang WR Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):83-6. PubMed ID: 18681306 [TBL] [Abstract][Full Text] [Related]
6. [Reduced intensity of BuCy conditioning regimen for transplantation in the treatment of malignant hematologic diseases]. Chen H; Lu DP; Huang XJ; Liu KY; Xu LP; Han W; Ren HY; Chen YH; Liu DH; Lu J; Jiang Q Zhonghua Xue Ye Xue Za Zhi; 2005 May; 26(5):273-6. PubMed ID: 15949287 [TBL] [Abstract][Full Text] [Related]
7. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia]. Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032 [TBL] [Abstract][Full Text] [Related]
8. [Second allogeneic transplant for leukemia relapsed after first allogeneic transplantation]. Yang DL; Han MZ; Feng SZ; Wang M; Zou DH; Wei JL; Yan ZS; Zhou SY; Liu QG; Jiang EL; Huang Y; Wang HH; Zhou Z; Zhai WJ; Yan WW; Han ZC Zhonghua Xue Ye Xue Za Zhi; 2004 May; 25(5):285-9. PubMed ID: 15182537 [TBL] [Abstract][Full Text] [Related]
9. [Therapeutic efficacy of hematopoietic stem cell transplantation in patients with chronic myelogenous leukemia]. Liu QF; Fan ZP; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY Di Yi Jun Yi Da Xue Xue Bao; 2004 Nov; 24(11):1227-9, 1241. PubMed ID: 15567763 [TBL] [Abstract][Full Text] [Related]
11. [Effects of allogeneic hematopoietic stem cell transplantation with very-high-dose conditioning regimen for refractory leukemia]. Liu QF; Sun J; Xu D; Zhang Y; Fan ZP; Wei YQ; Meng FY; Zhou SY Di Yi Jun Yi Da Xue Xue Bao; 2004 Oct; 24(10):1117-9. PubMed ID: 15485779 [TBL] [Abstract][Full Text] [Related]
12. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR; Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337 [TBL] [Abstract][Full Text] [Related]
13. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W; J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954 [TBL] [Abstract][Full Text] [Related]
14. [Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission]. Wang HH; Feng SZ; Wang M; Wei JL; Jiang EL; Zhang L; Huang Y; Zhou SY; Liu QG; Qiu LG; Han MZ; Yan WW Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):389-92. PubMed ID: 15355688 [TBL] [Abstract][Full Text] [Related]
15. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801 [TBL] [Abstract][Full Text] [Related]
16. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia]. Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060 [TBL] [Abstract][Full Text] [Related]
17. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia]. Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125 [TBL] [Abstract][Full Text] [Related]
18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
19. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy. Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257 [TBL] [Abstract][Full Text] [Related]
20. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation. Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]